Charles River Laboratories International
Stock Forecast, Prediction & Price Target
Charles River Laboratories International (CRL) stock Price Target by analysts
$188.67
Potential upside: 18.95%
Charles River Laboratories International price prediction
What is Charles River Laboratories International stock analysts` prediction?
Charles River Laboratories International stock forecast: Based on 3 Wall Street analysts` predicted price targets for Charles River Laboratories International in the last 3 months, the avarage price target is $188.67, with a high forecast of $NaN. The average price target represents a 18.95% change from the last price of $158.6.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Charles River Laboratories International stock Price Target by analysts
Full breakdown of analysts given Charles River Laboratories International price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Luke Sergott Barclays | 0% 0/2 | 11 months ago | $205 29.25% upside | $193.14 | TheFly | Previous targets (1) |
Jamie Clark Redburn Partners | 0% 0/1 | 11 months ago | $151 -4.79% downside | $192.97 | TheFly | Previous targets (0) |
Ann Hynes Mizuho Securities | 0% 0/1 | 12 months ago | $210 32.40% upside | $206.44 | StreetInsider | Previous targets (0) |
Justin Bowers Deutsche Bank | 0% 0/1 | about 1 year ago | $240 51.32% upside | $200.34 | TheFly | Previous targets (0) |
Eric Coldwell Robert W. Baird | 0% 0/1 | about 1 year ago | $239 50.69% upside | $201.85 | TheFly | Previous targets (0) |
Luke Sergott Barclays | 0% 0/2 | about 1 year ago | $230 45.01% upside | $207.35 | StreetInsider | Previous targets (1) |
Matthew Sykes Goldman Sachs | 0% 0/1 | over 1 year ago | $290 82.84% upside | $216.12 | StreetInsider | Previous targets (0) |
Elizabeth Anderson Evercore ISI | 0% 0/2 | over 1 year ago | $265 67.08% upside | $230.09 | StreetInsider | Previous targets (1) |
Elizabeth Anderson Evercore ISI | 0% 0/2 | over 1 year ago | $300 89.15% upside | $270.95 | StreetInsider | Previous targets (1) |
Donald Hooker KeyBanc | 0% 0/1 | over 3 years ago | $300 89.15% upside | $257.51 | Pulse 2.0 | Previous targets (0) |
David Windley Jefferies | 0% 0/2 | over 3 years ago | $280 76.54% upside | $273.03 | TheFly | Previous targets (1) |
David Windley Jefferies | 0% 0/2 | over 3 years ago | $464 192.55% upside | $357.95 | TipRanks Contributor | Previous targets (1) |
David Toung Argus Research | 0% 0/1 | almost 4 years ago | $440 177.42% upside | $377.51 | StreetInsider | Previous targets (0) |
Daniel Brennan Cowen & Co. | 0% 0/1 | about 4 years ago | $465 193.19% upside | $417.45 | TheFly | Previous targets (0) |
Katie Tryhane Credit Suisse | 100% 1/1 | about 4 years ago | $385 142.74% upside | $416.31 | StreetInsider | Previous targets (0) |
Tycho Peterson J.P. Morgan | 100% 1/1 | over 4 years ago | $390 145.90% upside | $337.99 | TheFly | Previous targets (0) |
Sandy Draper Guggenheim | 100% 1/1 | over 4 years ago | $369 132.66% upside | $329.52 | TheFly | Previous targets (0) |
Charles River Laboratories International Financial Estimates
Charles River Laboratories International Revenue Estimates
Charles River Laboratories International EBITDA Estimates
Charles River Laboratories International Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/25/2021 | 12/31/2022 | 12/30/2023 | 12/30/2025 | 12/31/2025 | 12/30/2026 | 12/30/2027 |
Revenue
% change YoY
| $3.54B N/A | $3.97B 12.31% | $4.12B 3.85% | Avg: $4.53B Low: $4.45B High: $4.56B avg. 9.82% | Avg: $4.68B Low: $4.62B High: $4.76B avg. 3.36% | Avg: $4.87B Low: $4.81B High: $4.93B avg. 3.98% | Avg: $4.80B Low: $4.74B High: $4.86B avg. -1.45% |
Net Income
% change YoY
| $390.98M N/A | $486.22M 24.36% | $474.62M -2.38% | Avg: $512.07M Low: $485.18M High: $528.40M avg. 7.88% | Avg: $549.81M Low: $494.02M High: $582.26M avg. 7.37% | Avg: $596.25M Low: $550.01M High: $630.78M avg. 8.44% | Avg: $727.52M Low: $716.54M High: $740.02M avg. 22.01% |
EBITDA
% change YoY
| $820.16M N/A | $986.14M 20.23% | $1.03B 4.66% | Avg: $1.09B Low: $1.07B High: $1.10B avg. 6.09% | Avg: $1.06B Low: $1.05B High: $1.08B avg. -2.53% | Avg: $1.17B Low: $1.16B High: $1.19B avg. 10.27% | Avg: $1.15B Low: $1.14B High: $1.17B avg. -1.45% |
EPS
% change YoY
| $7.77 N/A | $9.57 23.16% | $9.27 -3.13% | Avg: $9.72 Low: $9.43 High: $10.27 avg. 4.81% | Avg: $10.53 Low: $9.63 High: $11.35 avg. 8.33% | Avg: $11.49 Low: $10.69 High: $12.26 avg. 9.12% | Avg: $14.14 Low: $13.93 High: $14.38 avg. 23.09% |
Operating Expenses
% change YoY
| $744.77M N/A | $811.67M 8.98% | $885.29M 9.06% | Avg: $817.99M Low: $803.58M High: $823.40M avg. -7.60% | Avg: $859.37M Low: $848.30M High: $873.49M avg. 5.05% | Avg: $879.19M Low: $868.99M High: $890.81M avg. 2.30% | Avg: $866.36M Low: $856.31M High: $877.81M avg. -1.45% |
FAQ
What is Charles River Laboratories International stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 11.43% in 2025-2027.
We have gathered data from 10 analysts. Their low estimate is 485.18M, average is 512.07M and high is 528.40M.
What is Charles River Laboratories International stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 3.92% in 2025-2027.
We have gathered data from 12 analysts. Their low revenue estimate is $4.45B, average is $4.53B and high is $4.56B.
What is Charles River Laboratories International stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 11.34% in 2025-2027.
We have gathered data from 10 analysts. Their low earnings per share estimate is $9.43, average is $9.72 and high is $10.27.
What is the best performing analyst?
In the last twelve months 3 analysts have been covering Charles River Laboratories International stock. The most successful analyst is Luke Sergott.